Prevalence of major adverse cardiac events in men with prostate cancer receiving androgen deprivation therapy in real-world clinical practice.
Why the study?
ADT is associated with increased MACE risk in prostate cancer, but the prevalence of MACE in real-world clinical practice is unknown.
Do GnRH antagonists reduce the rate of major adverse cardiac events compared to GnRH agonists in men with prostate cancer receiving androgen deprivation therapy?
Population
17,336 men with prostate cancer newly initiating ADT in the United States
Comparison
GnRH antagonists vs GnRH agonists, and pre- vs post-relugolix approval
Design
Observational database study
Follow-up
126 days for antagonists vs 189 days for agonists
Key result
GnRH antagonist users had 36-37% lower 2- and 3-point MACE prevalence (2.3 vs 3.6 and 2.6 vs 4.1 per 100 person-years) than agonist users in real-world ADT.
Authors
Loading...
May support GnRH antagonists over agonists for ADT in high-CV-risk prostate cancer; extends RCT data but leaves open need for confirmatory trials.
Do GnRH antagonists reduce the rate of major adverse cardiac events compared to GnRH agonists in men with prostate cancer receiving androgen deprivation therapy?
In real-world practice, men with prostate cancer receiving GnRH antagonists had numerically lower rates of major adverse cardiac events compared to those receiving GnRH agonists.
Hahn et al. (2026) studied this question. GnRH antagonist users had 36-37% lower 2- and 3-point MACE prevalence (2.3 vs 3.6 and 2.6 vs 4.1 per 100 person-years) than agonist users in real-world ADT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: